CA-074: Selective Cathepsin B Inhibitor for Cancer Metastasis and Neurotoxicity Research

Executive Summary: CA-074 is a low-nanomolar, highly selective inhibitor of cathepsin B, with negligible cytotoxicity at standard in vitro concentrations and proven in vivo efficacy (Ki = 2–5 nM) (APExBIO). Cathepsin B is a lysosomal cysteine protease centrally implicated in cancer metastasis, regulated cell death (including necroptosis), and neurotoxicity (Liu et al., 2024). CA-074 blocks cathepsin B with >10,000-fold selectivity versus cathepsins H/L (Ki = 40–200 μM for H/L), enabling precise dissection of proteolytic cascades (CA-074.com). In cancer models, CA-074 reduces bone metastasis and modulates immune responses by shifting Th-2 to Th-1 phenotypes. The compound is soluble in DMSO, ethanol, and water with appropriate handling, and is validated for both cell-based and in vivo workflows (Amyloid-B-Peptide.com).

Biological Rationale

Cathepsin B is a lysosomal cysteine protease essential for protein turnover and regulated cell death pathways (Liu et al., 2024). During necroptosis, activated MLKL polymerizes on lysosomal membranes, causing lysosomal membrane permeabilization (LMP) and release of cathepsin B into the cytosol. This release leads to proteolytic cascades that dismantle cellular architecture, contributing to both tumor progression and neurotoxic injury. Cathepsin B also modulates immune responses via helper T-cell switching, impacting the Th-2/Th-1 balance. Dysregulated cathepsin B activity is implicated in tumor invasion, metastasis, and inflammatory neurodegeneration. Thus, selective inhibition of cathepsin B is a strategic approach for dissecting and modulating these critical biological pathways.

Mechanism of Action of CA-074, Cathepsin B inhibitor

CA-074 is a synthetic, small-molecule inhibitor that blocks the active-site cysteine of cathepsin B through covalent and non-covalent interactions. The compound exhibits a Ki of 2–5 nM for cathepsin B, and is over 10,000-fold less potent against cathepsins H and L (Ki = 40–200 µM), establishing a selectivity benchmark (APExBIO). Upon lysosomal membrane permeabilization, as observed in necroptosis or cancer cell invasion, released cathepsin B cleaves structural and regulatory proteins. CA-074 inhibits these proteolytic events, thus blocking downstream effects such as cell death, extracellular matrix degradation, and immune reprogramming. In immune cells, CA-074 reduces Th-2 cytokine-driven IgE/IgG1 production and shifts T-helper cell responses toward Th-1 dominance.

Evidence & Benchmarks

• CA-074 inhibits cathepsin B with a Ki of 2–5 nM, and is >10,000-fold selective over cathepsins H and L (Ki = 40–200 µM) (APExBIO).
• In a 4T1.2 breast cancer mouse model, intraperitoneal CA-074 (50 mg/kg) reduced bone metastasis without affecting primary tumor growth (Liu et al., 2024).
• CA-074 suppresses neurotoxicity in primary neuronal cultures exposed to Abeta42-activated microglia, implicating cathepsin B in neurodegenerative processes (CA-074.com).
• In vitro, CA-074 displays negligible cytotoxicity at 10 mM in cell culture systems (Amyloid-B-Peptide.com).
• Chemical inhibition of cathepsin B by CA-074 protects cells from TNF/Smac-mimetic/Z-VAD-induced necroptosis, confirming its utility in dissecting regulated cell death pathways (Liu et al., 2024).
• CA-074 modulates immune response by shifting Th-2 to Th-1 T-helper cell profiles and reducing IgE/IgG1 antibody production (AP24534.com).

This article extends recent reviews such as CA-074.com by providing updated evidence from 2024 necroptosis studies and by detailing immune modulation benchmarks not previously emphasized. For in-depth assay protocols and scenario-driven cell death assay guidance, see Amyloid-B-Peptide.com; here we focus on cross-pathway selectivity and translational relevance.

Applications, Limits & Misconceptions

Applications:

• Dissection of cathepsin B–dependent metastasis in preclinical cancer models.
• Investigation of necroptosis and lysosomal membrane permeabilization in regulated cell death.
• Assessment of neurotoxicity mechanisms involving microglial activation and protease release.
• Immune response modulation studies, including Th-2/Th-1 switching and antibody profiling.

Common Pitfalls or Misconceptions

• Not a pan-cathepsin inhibitor: CA-074 is highly selective for cathepsin B and does not significantly inhibit cathepsins D, H, or L at standard concentrations (APExBIO).
• Not effective for all forms of cell death: CA-074 blocks cathepsin B–mediated necroptosis but may not prevent apoptosis or other non-cathepsin B–dependent pathways (Liu et al., 2024).
• Solubility limitations in aqueous buffers: CA-074 requires DMSO, ethanol, or ultrasonic assistance for maximal solubility; improper dissolution can lead to precipitation or inconsistent results.
• Short-term solution stability: Prepared solutions are stable only for short-term use and should not be stored long-term at room temperature or above 4°C (APExBIO).
• In vivo efficacy is model-dependent: CA-074 reduces metastasis in certain models but does not affect primary tumor growth, highlighting the importance of context-specific interpretation (Liu et al., 2024).

Workflow Integration & Parameters

CA-074 (SKU A1926, APExBIO) is supplied as a crystalline solid, with a molecular weight of 383.44 g/mol and the chemical name (2S)-1-[(2S,3S)-3-methyl-2-[[(3S)-3-(propylcarbamoyl)oxirane-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carboxylic acid. The compound is soluble in DMSO (>19.17 mg/mL), ethanol (>31.3 mg/mL), and water (>5.91 mg/mL with ultrasonic assistance). For cell culture, stock solutions are typically prepared in DMSO and diluted to achieve working concentrations (e.g., 1–100 μM). In vivo, intraperitoneal injection at 50 mg/kg has demonstrated efficacy in reducing metastasis in mouse models. Storage at –20°C is recommended; solutions should be freshly prepared and used promptly. For additional guidance on assay optimization, see Optimizing Cell Death Assays with CA-074, which details practical troubleshooting steps and comparative cytotoxicity data.

Conclusion & Outlook

CA-074, Cathepsin B inhibitor, is a validated, highly selective tool for probing cathepsin B–mediated pathways in cancer metastasis, neurotoxicity, and immune modulation. Its nanomolar potency, minimal cytotoxicity, and robust in vivo benchmarks position it as a gold standard in the field. Ongoing research, including recent advances in necroptosis mechanism elucidation, further underscores its translational value (Liu et al., 2024). As the landscape of cell death and immune modulation research evolves, CA-074 will remain an indispensable reagent for dissecting cysteine protease–driven processes. For ordering and technical data, refer to the APExBIO product page.